Sugi Predict

Sugi Predict / Compounds / SCHEMBL15399530

SCHEMBL15399530

SCHEMBL15399530

CO[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H]1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.46
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ PDE4B Q07343 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ DDB1 Q16531 1/20 0.36
▸ CRBN Q96SW2 1/20 0.36
▸ NAMPT P43490 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ RORC P51449 1/20 0.36
▸ EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13350207 1.00 NR1H2 (0.46) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL376554 1.00 NR1H2 (0.46) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL13232686 1.00 NR1H2 (0.46) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL9773777 1.00 NR1H2 (0.46) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL9773778 1.00 NR1H2 (0.46) NR1H2USP2SMN1; SMN2USP30CHRM2
Hydrochloric Acid SCHEMBL15391280 0.98 NR1H2 (0.45) NR1H2USP2SMN1; SMN2USP30CHRM2
Hydrochloric Acid SCHEMBL15391278 0.98 NR1H2 (0.45) NR1H2USP2SMN1; SMN2USP30CHRM2
Hydrochloric Acid SCHEMBL15391276 0.98 NR1H2 (0.45) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL21588925 0.88 NR1H2 (0.53) NR1H2USP2SMN1; SMN2USP30CHRM2
SCHEMBL71366 0.88 NR1H2 (0.53) NR1H2USP2SMN1; SMN2USP30CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4169575-B1 CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS SATO PHARMA (JP) 2026-01-07 — — EP disclosed
US-12497382-B2 GLP-1R modulating compounds GILEAD SCIENCES, INC. (US) 2025-12-16 — — US disclosed
CN-115667259-B Fused ring compounds for inhibiting H-PGDS 佐藤制药株式会社 2025-06-17 — — CN disclosed
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS INCYTE CORP (US) 2025-06-12 — — US disclosed
EP-4548918-A2 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS Incyte Corporation (US) 2025-05-07 — — EP disclosed
CN-119874674-A GLP-1R modulating compounds 吉利德科学公司 2025-04-25 — — CN disclosed
CN-114630823-B GLP-1R Modulating Compounds 吉利德科学公司 2025-01-28 — — CN disclosed
US-12157746-B2 Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2024-12-03 — — US disclosed
CN-112204028-B tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-12-29 — — CN disclosed
US-20230391747-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2023-12-07 — — US disclosed
US-9884048-B2 ERK inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-06 — — US disclosed
EP-3233858-A1 ERK INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-25 — — EP disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 — — US disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 — — US disclosed
US-20170266167-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 — — US disclosed
WO-2016100050-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 — — WO disclosed
WO-2016095089-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 — — WO disclosed
EP-2678329-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-11-18 — — EP disclosed
US-8889704-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-18 — — US disclosed
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-01-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140005213-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 NR1H2 3551/4885USP2 4137/4885SMN1; SMN2 3759/4885
US-20170266167-A1 ERK INHIBITORS MAPK1, MAPK3, MAPK6 NR1H2 658/4885USP2 2957/4885SMN1; SMN2 3550/4885
US-20250188073-A1 TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS KRAS, NRAS, HRAS NR1H2 997/4885USP2 2160/4885SMN1; SMN2 3775/4885
US-20230391747-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 NR1H2 486/4885USP2 2853/4885SMN1; SMN2 1956/4885
US-12157746-B2 Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease HLA-DRB1, SSB, REN NR1H2 295/4885USP2 4637/4885SMN1; SMN2 1173/4885
US-12497382-B2 GLP-1R modulating compounds GLP1R, GIPR, GPR119 NR1H2 486/4885USP2 2853/4885SMN1; SMN2 1956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.